Dutkiewicz 1996.

Methods	Single‐site study. Double blinded: no. Randomization: unclear Patients not blinded: Providers not blinded: Lost to follow‐up: none
Participants	N=89 Polish men with symptomatic BPH. Age range: 50‐68. Lost to follow‐up: 0.
Interventions	Control: Cernilton 2 tablets three times daily x 2 weeks followed by 1 tablet three times daily up to 4 months (n=51). Treatment: Tadenan 2 tablets twice daily (38). Treatment duration: 24 weeks.
Outcomes	Obstructive symptom score Irritative symptom score; peak urine flow; residual volume; prostate volume. Adverse events.
Notes	Exclusions: No details provided.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear